| CORVUS PHARMAC. DL-,0001 |
| USA |
| Gesundheit |
| US2210151005 / A2AFXS |
| C17 (Frankfurt) / CRVS (NASDAQ) |
| FRA:C17, ETR:C17, C17:GR, NASDAQ:CRVS |
| - |
| https://www.corvuspharma... |
|
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases. Its primary emphasis is on ITK inhibition through its lea..
>Volltext.. |
| 1141.7 Mio. EUR |
| 1094.15 Mio. EUR |
| - |
| -36.6 Mio. EUR |
| -13.05 Mio. EUR |
| -0.14 EUR |
| 0.8 Mio. EUR |
| 3.91 Mio. EUR |
| -28 Mio. EUR |
| 6.05 |
| - |
| 78.38% |
| - |
| - |
| - |
| - |
| CORVUS PHARMA, CORVUS PHARMACEUTICALS, CORVUS PHARMACEUTICAL |
| 29.04.26 |
|